featured
Rivaroxaban vs Placebo in High-Risk Adults With Mild COVID
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized study of rivaroxaban vs. placebo on disease progression and symptoms resolution in high-risk adults with mild COVID-19
Clin. Infect. Dis. 2021 Sep 15;[EPub Ahead of Print], J Ananworanich, R Mogg, MW Dunne, M Bassyouni, CV David, E Gonzalez, T Rogalski-Salter, H Shih, J Silverman, J Medema, P HeatonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.